Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...

Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune ...

The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...

Mayo Clinic scientists are exploring an unusual but promising strategy to treat one of the deadliest bile duct cancers by turning milk into a microscopic delivery system for gene therapy. Their work ...

The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that ...

Background Sex-based differences in immune response are well established, but whether men and women derive comparable benefit ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

Chemotherapy has been the standard for previously untreated advanced or metastatic HER2-mutant lung cancer. In this phase I ...

In this Healio video, Alissa J. Cooper, MD, a thoracic oncologist at Dana-Farber Cancer Institute, discusses the Beamion LUNG-1 trial evaluating zongertinib in HER2-mutant advanced non-small cell lung ...

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

The FDA grants Priority Review to ifinatamab deruxtecan for adult patients with extensive-stage small cell lung cancer progressing on or after platinum-based chemotherapy.

The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.